The forest plots of pooled estimates of standardized mean differences of circulating apelin (A), apelin/HDL-c (B), apelin/LDL-c (C), apelin/triglycerides (D), and apelin/total chol... by Hamed Akbari (8119361)

Subjects:

rHSP60 decreases LPS-induced mononuclear cell proliferation. by Igor Emiliano L. Souza (18196495)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

Mass Spectrometry Experiment 1: Comparison of Mito Matrix and Vpu WT and mutants. by Charlotte A. Stoneham (10819125)

Decreased vagal activity and deviation in sympathetic activity precedes development of diabetes by Da Young Lee (8617365)

“…In Cox analysis, as SDNN, RMSSD, and normalized HF tertiles increased, the risk of diabetes decreased [hazard ratios (95% confidence intervals) of tertile 3: 0.81 (0.70-0.95), 0.76 (0.65-0.90) and 0.78 (0.67-0.91), respectively], whereas the risk of diabetes increased in the case of heart rate, normalized LF, and LF/HF ratio [hazard ratios (95% confidence intervals) of tertile 3: 1.41 (1.21-1.65), 1.32 (1.13-1.53), and 1.31 (1.13-1.53), respectively] after adjusting for age, sex, body mass index, smoking, drinking, systolic blood pressure, lipid level, c-reactive protein, and homeostasis model assessment of insulin resistance.…”

Brain uptake rate of [¹⁴C]docosahexaenoic acid (DHA) in the whole brain and each brain region. by Takuro Iwao (14636741)

Subjects: